Products
Ersodetug Biosimilar Monoclonal Antibody (Insulin Receptor) for Research
Cat No.: GMP-Bios-INN-1188
Anti-INSR/CD220 therapeutic antibody (Pre-made Ersodetug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ersodetug (development code RZ-358) is a monoclonal antibody targeting the insulin receptor (INSR). It is developed by XOMA and Rezolute for congenital hyperinsulinism, hypoglycaemia. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1188-1mg | 1mg | 3090 |
| GMP-Bios-INN-1188-10mg | 10mg | |
| GMP-Bios-INN-1188-100mg | 100mg | |
| GMP-Bios-INN-1188-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ersodetug biosimilar, Whole mAb, Anti-INSR/CD220 Antibody: Anti-INSR/CD220/Insulin receptor/IR therapeutic antibody |
| INN Name | Ersodetug |
| Target | INSR/CD220 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | XOMA;Rezolute |
| Conditions Approved | na |
| Conditions Active | Congenital hyperinsulinism;Hypoglycaemia |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
